CIK: 0001792206 · Show all filings
Period: Q4 2021 (← Previous) (Next →)
Filing Date: Feb 11, 2022
Total Value ($000): $407,014 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | Pardes Biosciences Inc | 9,400,515 | $153,886 | 37.8% | $16.37 | — | COM | 69945Q105 |
| — | Somalogic, Inc. | 5,326,472 | $62,000 | 15.2% | $12.39 | — | COM CL A | 83444K105 |
| — | TheseusPharmaceuticals, Inc. | 3,212,732 | $40,737 | 10.0% | $12.68 | — | COM | 88369M101 |
| QSI | Quantum-Si Incorporated | 2,342,061 | $18,432 | 4.5% | $10.48 | -28.1% | COM CL A | 74765K105 |
| ACRS | Aclaris Therapeutics, Inc. | 1,258,243 | $18,295 | 4.5% | $19.56 | -22.5% | COM | 00461U105 |
| CGEM | Cullinan Oncology, Inc. | 1,143,006 | $17,637 | 4.3% | $40.60 | -50.9% | COM | 230031106 |
| HLTHQ | Cue Health Inc. | 1,167,782 | $15,660 | 3.8% | $11.81 | — | COM | 229790100 |
| — | Kinnate Biopharma Inc. | 875,001 | $15,505 | 3.8% | $39.78 | — | COM | 49705R105 |
| CMPX | Compass Therapeutics, Inc. | 4,400,000 | $13,948 | 3.4% | $3.29 | 0.0% | COM | 20454B104 |
| IVVD | Adagio Therapeutics, Inc. | 1,745,060 | $12,669 | 3.1% | $34.15 | -23.9% | COM | 00534A102 |
| — | Adicet Bio, Inc. | 680,000 | $11,893 | 2.9% | $17.49 | — | COM | 007002108 |
| HIMS | Hims & Hers Health, Inc. | 1,706,922 | $11,180 | 2.7% | $13.13 | -44.9% | COM CL A | 433000106 |
| — | Gemini Therapeutics, Inc. | 2,435,125 | $7,086 | 1.7% | $13.55 | — | COM | 36870G105 |
| — | Research Alliance Corp. II | 500,000 | $4,885 | 1.2% | $10.25 | — | COM CL A | 760873109 |
| — | 23andMe Holding Co. | 406,913 | $2,710 | 0.7% | $11.69 | — | COM CL A | 90138Q108 |
| PHVS | Pharvaris N.V. | 34,142 | $491 | 0.1% | $31.46 | -50.3% | COM | N69605108 |